Rivaroxaban in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention in Clinical Practice

Little is known about the efficacy and safety of rivaroxaban in patients with atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI) in clinical practice. We therefore conducted a prospective observational study to determine the rate of ischemic, embolic, and bleeding events...

Full description

Saved in:

Bibliographic Details
Published in:	The American journal of cardiology Vol. 189; pp. 31 - 37
Main Authors:	Zeymer, Uwe, Toelg, Ralph, Wienbergen, Harm, Hobbach, Hans-Peter, Cuneo, Alessandro, Bekeredjian, Raffi, Ritter, Oliver, Hailer, Birgit, Hertting, Klaus, Hennersdorf, Marcus, Scholtz, Werner, Lanzer, Peter, Mudra, Harald, Schwefer, Markus, Schwimmbeck, Peter-Lothar, Liebetrau, Christoph, Thiele, Holger, Claas, Christoph, Riemer, Thomas, Zahn, Ralf
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 15-02-2023 Elsevier Limited
Subjects:	Acute coronary syndromes Angioplasty Anticoagulants Anticoagulants - therapeutic use Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Bleeding Cardiac arrhythmia Cardiovascular disease Cerebral infarction Clinical medicine Consortia Drug Therapy, Combination Fibrillation Fibrinolytic Agents - therapeutic use Heart attacks Hemorrhage - chemically induced Hemorrhage - epidemiology Humans Implants Ischemia Myocardial infarction Observational studies Participation Patients Percutaneous Coronary Intervention - adverse effects Platelet Aggregation Inhibitors - therapeutic use Prospective Studies Rivaroxaban Stroke Thromboembolism Thrombosis Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!